Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ITM Isotopen Technologien München AG

http://www.itm.ag

Latest From ITM Isotopen Technologien München AG

Fundraising Tips From The Top Of European Biotech

The biotech sector is awash with capital and the rise of the virtual roadshow is breaking down geographic barriers, giving European firms a better chance to impress US investors.

Financing Leadership

Finance Watch: Insilico Raises $255m To Take AI-Discovered Drugs Into The Clinic

Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.

Financing Innovation

Novartis Broadens VISION On Radioligands

Phase III trial presented at ASCO shows 177lutetium-PSMA-617 improved radiographic PFS and OS in advanced prostate cancer patients. Novartis execs say the firm is ready for the marketing challenge. 

ASCO Cancer

ITM Charts A Path From Radionuclides To Radiotherapeutics And Attracts Financing

Interview: Germany’s ITM is executing on its plan to develop targeted radionuclide-based therapies with its lead lutetium-177 product in Phase III trials supported by a just closed $109m financing.

Cancer Financing
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Other Names / Subsidiaries
    • ITG Isotope Technologies Garching GmbH
    • ITM Solucin GmbH
UsernamePublicRestriction

Register